Actually they are already thinking about Manufacturing and Prep for phase 2 (see allocation of funds chart).
Surprised not much more talk on the appointments.
A specialist with cannabidiol trial experience (epilepsy, Insys 1 billion MC), senior role with Medicis (bought out for 2.6 billion). A pretty niche experience, and they manage to snag a guy who has already done it.
As per announcement "“Very few people in the world have led the conduct of clinical trials involving cannabidiol, Mark’s experience in particular will guide our engagement with FDA and the Australian TGA as we move into clinical trials in early 2017.”
Ann: Botanix Secures Key Clinical and Manufacturing Staff-BOT.AX, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
-0.005(3.03%) |
Mkt cap ! $308.8M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.3¢ | 15.5¢ | $1.059M | 6.646M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 76 | 4258114 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 2704990 | 25 |
View Market Depth
| Last trade - 11.37am 30/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |